Nanomedicines for Breast Cancer Theranostics

Dr. Nanasaheb Thorat is Principal Investigator funded by the Science Foundation Ireland (SFI) and Irish Research Council (IRC) Pathway Program at the University of Limerick, Ireland. He is also a Marie Curie Visiting Research Scientist at the University of Oxford, UK.He has been deeply engaged in collaborative work with the many eminent scientists from Japan, USA, Germany, Korea, Ireland, India, Poland, Saudi Arabia and Australia. Dr. Thorat has received the European Commission’s innovation Radar “Grand Prix of the Innovation Radar Prize 2020” for developing ground-breaking technology for breast cancer theranostics. Joanna Bauer is Assistant Professor at the Department of Biomedical Engineering at the Wroclaw University of Science and Technology, Poland. Her research focuses on multidisciplinary biomedical engineering projects related to personalized and preventive medicine, nano-biomaterials synthesis, characterization and functionalization, biomedical optics using visible and infrared.imaging, as well as image analysis and pattern recognition.

• 1. Nanomedicine: next generation modality of breast cancer therapeutics2. Physical and Chemical properties of nanostructures3. Biological Perspectives of Hybrid nanostructures4. Novel hybrid nanostructures in breast cancer nanomedicine5. Synergy between nanoparticles and breast cancer theranostics6. Remotely stimulated Nano medicine for breast cancer therapy7. Functional Nanostructures for drug resistant breast cancer theranostics8. Nanomedicine for early diagnosis of breast cancer9. Nanomedicine strategies for chemoresistant breast cancer theranostics10. Cellular Interaction and Toxicity of Nanostructures11. Nano-pharmacokinetics, pharmacodynamics (PK/PD) and clinical relationship12. A New Approach for Cancer Treatment: from Specific Induction of Breast Cancer to Innovative Gold-Nanoparticle Mediated Thermal Therapies13. Development in efficacy assessment in relevant oncology models for breast cancer nanomedicine14. Consensus protocols for animal experimentation and nanomedicine trials at clinical stage in breast cancer15. Current development in toxicity, clinical trials guidelines for regulatory aspects of breast cancer nanomedicines16. Breast cancer nanomedicine market update and other industrial perspectives of nanomedicine